Alzheimer's disease (mild–moderate)

• CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil
  The purpose of this study was to determine if Dimebon® (latrepirdine) is safe and effective in patients with mild to moderate Alzheimer's disease on Aricept® (donepezil).
  
• A Phase 2 Study Evaluating the Efficacy and Safety of PF 04494700 in Mild to Moderate Alzheimer's Disease
  The purpose of this study was to evaluate the efficacy and safety of PF04494700 in participants with mild to moderate Alzheimer's disease.
  
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease
  The purpose of this study was to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease.
  
• A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
  This was a Phase I, multicenter, randomized, double-blind, placebo-controlled study in the United States and consisted of a single ascending-dose stage followed by a multidose, parallel-treatment stage. This study was conducted in approximately 50 adult patients between 50-85 years old who have mild to moderate Alzheimer's disease.
  

Frontotemporal dementia (FTD)

• A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
  The study was designed to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The study also assessed the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD); determined whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia; and evaluated whether memantine delays or decreases the emergence of parkinsonism in frontotemporal dementia. Lastly, the study was designed to determine whether treatment with memantine affects change in weight.